The DOI matches its Crossref record.
Central nervous system toxicity of interferon
Open accessAbstract
The potential role of Interferon (IFN) in the treatment of malignant disease is currently being evaluated. Some central nervous system (CNS) toxicity, usually manifested by drowsiness or confusion has been recorded with all IFN preparations, almost regardless of the dose and schedule (Priestman 1980, Scott et al., 1981) and it was shown to be the major dose-limiting toxicity when high doses of IFN derived from Namalwa lymphoblastoid cells (HuIFN-aN) were administered by continuous i.v. infusion (Rohatiner et al., 1982). It was therefore decided to undertake a formal study of the CNS side effects of HuIFN-axN and gene-cloned HuIFN-a2, given at the dose selected on the basis of Phase I Studies for the treatment of myelogenous leukaemia. The results of this study comprising clinical examination, serial electroencephalography (EEG), investigation of eye movements, biochemical tests of metabolic function and serum and cerebrospinal fluid IFN levels are presented below. Eleven patients were investigated, 8 prospectively (4 acute myelogenous leukaemia (AML), 2 chronic myeloid leukaemia (CML), 1 chronic lymphocytic leukaemia (CLL) and 1 follicular lymphoma) and 3 retrospectively (AML). The latter are included because of the inevitably limited data concerning cerebrospinal fluid IFN concentrations. Seven patients received HuIFN-axN (Wellcome Research Laboratories, specific activity: 2.13 x 108 u.mgprotein). Four patients were treated with gene-cloned HuIFN-CX2 (Schering Plough, specific activity: >2 x 108u.mgprotein). All patients received 100x 106u.m-2 per day administered by continuous i.v. infusion for 7 days, with the exception of one patient who received a second cycle at half the dose and another (in the Phase I study) who received 200 x 106 u.m-2 per day for 5 days. Clinical toxicity was assessed by daily observation of the general demeanour of the patient and direct questioning aimed at eliciting any
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
DENICOFF, K. D., RUBINOW, D. R., PAPA, M. Z., SIMPSON, C., SEIPP, C. A., LOTZE, M. T., CHANG, A. E., ROSENSTEIN, D., & ROSENBERG, S. A. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-293 · Cited by 455
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Cancer-treatment-induced neurotoxicity—focus on newer treatments
Stone, J. B., & DeAngelis, L. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.152 · Cited by 274
Metadata
- Authors
- Rohatiner, A. Z., Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A.
- Venue
- British Journal of Cancer
- Published
- 1983-03
- Volume
- 47
- Issue
- 3
- Pages
- 419-422
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2040423395
- Cited by
- 183
- References
- 0
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Central nervous system toxicity of interferon. https://app.cochat.ai/papers/10.1038/bjc.1983.63
- The paper
- Rohatiner, A. Z., Prior, P. F., Burton, A. C., Smith, A. T., Balkwill, F. R., & Lister, T. A. (1983). Central nervous system toxicity of interferon. British Journal of Cancer. https://doi.org/10.1038/bjc.1983.63
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.